February 29, 2024 – OssDsign AB (publ.) right now broadcasts that the corporate’s present VP of Technique, Enterprise Improvement and Regulatory Affairs, Tom Buckland, has been appointed Chief Technical Officer (CTO). The promotion is a key a part of the corporate’s change of route right into a pure-play orthobiologics firm focusing completely on the U.S. Market.
Tom Buckland, at the moment VP of Technique, Enterprise Improvement and Regulatory Affairs, will in his new position be answerable for Operations & Manufacturing, Analysis & Improvement in addition to High quality Assurance and Regulatory Affairs.
“For the reason that Acquisition of Sirakoss in 2020, Tom Buckland has been an instrumental member of the staff. Appointing him as our new CTO is a crucial step in OssDsign’s transformation right into a pureplay orthobiologics firm. His scientific background mixed together with his huge operational expertise from main positions in spine and orthobiologics corporations might be pivotal for the corporate’s journey ahead”, mentioned Morten Henneveld, CEO of OssDsign.
Tom Buckland joined OssDsign via the acquisition of Sirakoss, the place he was the CEO. His earlier experiences embody main positions at Nuvasive, Apatech and Baxter in addition to working as a good advisor to start- and scale-up corporations. Tom Buckland holds a Masters’ diploma in Mechanical Engineering and a Ph.D. in Biomaterials from the College of London.
For additional data, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, e-mail: morten.henneveld@ossdsign.com
Licensed Adviser
The Firm’s Licensed Adviser is Carnegie Funding Financial institution AB (publ)
About OssDsign
OssDsign is a developer and international supplier of subsequent era bone alternative merchandise. Primarily based on innovative materials science, the corporate develops and markets merchandise that help the physique’s personal therapeutic capabilities and thereby enhance the scientific end result in a variety of orthopedic areas with excessive medical wants. With a product portfolio consisting of patient-specific implants for cranial surgical procedures and an off-the-shelf artificial bone graft for spine surgical procedures, OssDsign give sufferers again the life they deserve. The corporate has a powerful industrial presence within the U.S., Europe and chosen Asian international locations. OssDsign’s share is traded on Nasdaq First North Progress Market in Stockholm, Sweden.
Discussion about this post